CJC-1295 and Ipamorelin Are Not on the FDA Docket: The 2024 Votes Nobody Reads

What the 2026-2027 Docket Actually Contains

Two things happened in April 2026, and they are often collapsed into one. The FDA updated its interim 503A bulks list to remove twelve peptide bulk substances from Category 2. Separately, the agency published a Federal Register notice on April 16, 2026 scheduling the advisory committee consultations that would follow, with a public comment docket, FDA-2025-N-6895. That notice is what set the entire 2026-2027 review calendar, and it is a closed list. Substances not named in it are not queued for a vote.

|---|---|---|

Two details in that table are worth pausing on. First, the February 2027 batch has no published date, agenda time, or comment docket yet, so anyone quoting a specific 2027 meeting day is guessing. As of August 5, 2026, no Federal Register notice announcing that meeting has been published. Second, GHK-Cu was not voted on in July 2026 at all. The copper tripeptide sits in the second batch, which puts it on a completely separate clock from the six peptides that got recommendations in July. Those two facts alone account for a large share of the confusion circulating since the meeting.

The 2024 Votes Nobody Reads

The reason CJC-1295 and ipamorelin are absent from the 2026-2027 docket is not that the FDA overlooked them. It is that they were already handled, in a review cycle that ran a year and a half before the July 2026 meeting.

October 29, 2024. PCAC reviewed ipamorelin acetate and ipamorelin free base, alongside ibutamoren mesylate, L-theanine, and kisspeptin-10. The committee voted against all four nominated substances. The uses under review were specific rather than open-ended: ipamorelin was evaluated for growth hormone deficiency and postoperative ileus, ibutamoren mesylate for growth hormone deficiency, osteoporosis, hip fracture, sarcopenia, obesity and Alzheimer's disease, L-theanine for sleep and anxiety disorders, and kisspeptin-10 for secondary hypogonadism in men. Committee discussion centered on insufficient human efficacy data and unresolved safety questions, including fluid retention, a congestive heart failure signal, and hyperglycemia.

December 4, 2024. PCAC reviewed AOD-9604 and AOD-9604 acetate, the full CJC-1295 family covering free base, acetate, and the DAC variants including CJC-1295 DAC acetate and CJC-1295 DAC trifluoroacetate, and thymosin alpha-1 in free base and acetate forms. The committee voted against adding any of them to the 503A bulks list. The proposed uses on the agenda were AOD-9604 for obesity, CJC-1295 for growth hormone deficiency, and thymosin alpha-1 for a long list of infectious, oncologic and inflammatory indications.

Effectiveness and safety are separate findings, and they did not land the same way for every substance. Advocacy coverage of the December meeting from the Alliance for Natural Health pointed out that the FDA's own review material stated that in most clinical studies thymosin alpha-1 "has not been associated with significant adverse events attributable to Ta1" at subcutaneous doses of 1 to 16 mg for up to 12 months, and that the agency's concerns leaned on theoretical risks such as immunogenicity and impurities in bulk ingredients rather than documented harm. Whether you find that framing persuasive or not, the operative point for planning purposes is unchanged: the votes went against inclusion, and no subsequent vote has been scheduled to revisit them.

It is also worth being precise about the evidence distinction that runs through all of this. The human clinical record for growth-hormone-secretagogue peptides such as CJC-1295 and ipamorelin is limited, and a large share of what circulates as supporting evidence is preclinical or animal research. The two are not interchangeable, and regulatory reviews weight them very differently. Animal and cell-culture findings do not establish an effect in humans. The same asymmetry showed up in July 2026, where FDA scientific reviewers recommended against including all seven peptides on the 503A list, citing a lack of clinical data, and the committee recommended six of them anyway. Reporting from STAT and NPR noted that the recommendations passed over the objections of agency scientists, and STAT also reported that a majority of the panelists who voted yes had ties to the peptide industry.

Why "Not in Category 2" Is Not "Coming Back to the List"

Here is the specific trap that produces most of the bad 2027 planning. CJC-1295, ipamorelin acetate, thymosin alpha-1, and AOD-9604 are, in fact, not sitting in Category 2 of the interim 503A bulks list. The FDA announced on September 20, 2024 that it was removing them, along with Selank acetate, after the original nominators withdrew the nominations. The removal took effect seven days later, on September 27, 2024. That removal is exactly what teed up the October and December 2024 PCAC reviews.

So a coach or clinic manager checking the Category 2 list today will not find CJC-1295 on it, and may reasonably conclude that the compound is trending toward availability. The opposite is closer to the truth. These four moved out of Category 2 and then went through advisory review and were voted down. They are not paused mid-process. They finished the process and did not clear it.

This is the same distinction covered in our post on the [FDA removing 12 peptides from Category 2](/blog/fda-503a-category-2-peptide-removal-2026), applied to an earlier and separate group of substances. Category 1 and Category 2 are interim sorting buckets used during evaluation. The 503A bulks list is the actual list a traditional compounding pharmacy may compound from. Leaving Category 2 places a substance nowhere in particular. It is a procedural waypoint, not a destination, and for the 2024 cohort the destination turned out to be a negative vote.

|---|---|

What the July 2026 Vote Did and Did Not Change

The July 23-24, 2026 meeting recommended adding six peptides to the 503A list and rejected one. The margins were narrow in every case. On July 23, BPC-157, KPV and TB-500 each cleared 8 to 6 with one abstention, and MOTS-c cleared 7 to 5 with two abstentions. On July 24, Semax cleared 8 to 5 with one abstention and Epitalon cleared 7 to 4 with one abstention, while emideltide, also called DSIP, failed 6 to 7 with one abstention.

Three things follow, and none of them touch the GH-axis peptides.

If you want to understand what these compounds are as a matter of pharmacology rather than paperwork, our explainers on the [CJC-1295 and ipamorelin pairing](/blog/ipamorelin-cjc-1295-protocol) and on [CJC-1295 with and without DAC](/blog/cjc-1295-dac-vs-no-dac) cover the mechanism and half-life differences. Neither of those posts asserted a pending FDA reinstatement, and nothing in this article contradicts them. They describe the compounds. This one describes the docket.

The One-Line Answer for Coaches and Clinics

If a client asks whether to build a 2027 plan around ipamorelin or CJC-1295 returning to the compounding list, the sourced one-liner is this: PCAC reviewed and rejected both in 2024, the 2026-2027 docket set by the April 2026 Federal Register notice does not include either one, and no new review has been scheduled, so there is no decision point to plan around.

If the follow-up is what is actually under review, the answer is the twelve peptides in the table above. Seven were voted on in July 2026 and five are queued for the meeting the FDA intends to hold before the end of February 2027. That is the complete list. Anything outside it, including every peptide in the 2024 cohort, has no pending vote.

Three habits keep you accurate over time. Check whether a substance appears in a published Federal Register notice before assuming a review exists, since every PCAC meeting is noticed there with a comment docket and the agendas and briefing materials are posted on the FDA advisory committee calendar. Distinguish a PCAC recommendation from a rulemaking action, because only the second one changes what a pharmacy may do. And treat a substance's absence from Category 2 as neutral information rather than positive news, since the 2024 cohort demonstrates that a substance can leave Category 2 and still be voted down. If a claim about a peptide's regulatory future cannot be traced to one of those public records, it is speculation.

What a client should actually do with a GH-axis question is a clinical conversation, not a regulatory one. Whether any compound is appropriate, and through what lawful channel it might be available, is a determination for a licensed prescriber who knows the person's history. A coach's job here is to keep the regulatory picture accurate so nobody builds a year of programming on a hearing that does not exist.

What to Track: Biomarkers Worth Monitoring

Regulatory status changes on its own schedule. Your data does not have to wait for it. People who work with clinicians on growth-hormone-axis questions commonly keep a longitudinal record of the following markers, and having that record already built is what makes any future conversation with a provider more productive. This is a list of what is commonly tracked, not a recommendation to test, start, or stop anything.

The value is in the trend, not the single reading. A one-off IGF-1 result pulled during a busy visit tells a provider very little. Six values across eighteen months, drawn under comparable conditions, give a clinician far more context to work with.

For plain-language background on the individual compounds, our library covers [CJC-1295](/peptides/cjc-1295), [ipamorelin](/peptides/ipamorelin), and [thymosin alpha-1](/peptides/thymosin-alpha-1) without treating any overview as a recommendation. MyProtocolStack organizes what you track and reports what the public record says. It does not interpret your data, and it is not a substitute for your clinician's judgment.

[Keep your labs and protocol history in one organized, provider-ready record with MyProtocolStack.](/auth/login?mode=signup)

Frequently Asked Questions

Is CJC-1295 coming back to the FDA compounding list?

There is no scheduled review that could put it there. PCAC reviewed the CJC-1295 family, covering free base, acetate, and the DAC variants, at its December 4, 2024 meeting and voted against adding it to the 503A bulks list. The 2026-2027 docket set by the April 2026 Federal Register notice covers twelve other peptides and does not include CJC-1295. No new review has been announced, so as of August 5, 2026 there is no pending decision point.

Was ipamorelin reviewed by the FDA advisory committee?

Yes. PCAC reviewed ipamorelin acetate and ipamorelin free base at its October 29, 2024 meeting, alongside ibutamoren mesylate, L-theanine, and kisspeptin-10, and voted against all four. Ipamorelin was evaluated for growth hormone deficiency and postoperative ileus. It is not on the July 2026 docket and not in the batch the FDA intends to bring to PCAC before the end of February 2027.

Which peptides are actually under FDA review in 2026 and 2027?

Twelve. At the July 23-24, 2026 meeting PCAC considered BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Semax, and Epitalon, recommending six and rejecting emideltide. A second batch of five, GHK-Cu, Melanotan II, cathelicidin LL-37, dihexa acetate, and PEG-MGF, is scheduled for consultation before the end of February 2027, with no specific date published yet. Nothing outside those twelve has a pending vote.

If CJC-1295 is not in Category 2 anymore, does that mean it is close to being approved?

No, and this is the most common misreading. The FDA announced on September 20, 2024 that CJC-1295, ipamorelin acetate, thymosin alpha-1, AOD-9604, and Selank acetate were being removed from Category 2, effective seven days later on September 27, 2024, which is what set up the 2024 PCAC reviews. Those reviews then voted against inclusion. Leaving Category 2 places a substance nowhere in particular. It is a procedural waypoint, and for this group the process concluded with a negative recommendation rather than a placement on the 503A bulks list. None of these is an FDA-approved drug.

Does the July 2026 BPC-157 vote help ipamorelin or CJC-1295?

No. PCAC recommendations apply only to the substances on that meeting's agenda, and they are advisory rather than binding on the FDA. Even for the six peptides recommended in July 2026, notice-and-comment rulemaking still has to occur before anything is added to the 503A bulks list, a process expected to begin in late 2026 or 2027 and potentially run longer. A favorable vote for one peptide creates no procedural path for a different peptide that was separately reviewed and rejected.

How narrow were the July 2026 votes?

Very. BPC-157, KPV and TB-500 each passed 8 to 6 with one abstention. MOTS-c passed 7 to 5 with two abstentions. Semax passed 8 to 5 with one abstention and Epitalon passed 7 to 4 with one abstention. Emideltide failed 6 to 7 with one abstention. FDA's own scientific reviewers had recommended against including all seven, citing a lack of clinical data.

Sources

1. Federal Register, "Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List," document 2026-07361, 91 FR 20465, published April 16, 2026. https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request

2. U.S. Food and Drug Administration, "July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee." https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026

3. U.S. Food and Drug Administration, "2026 Meeting Materials, Pharmacy Compounding Advisory Committee." https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/2026-meeting-materials-pharmacy-compounding-advisory-committee

4. McDermott Will & Emery, "Bulk-list bound? PCAC backs majority of peptides in two-day public meeting." https://www.mcdermottlaw.com/insights/bulk-list-bound-pcac-backs-majority-of-peptides-in-two-day-public-meeting/

5. Mintz, "FDA's Advisory Committee Votes on Peptides: What It Does and Doesn't Do," July 29, 2026. https://www.mintz.com/insights-center/viewpoints/2146/2026-07-29-fdas-advisory-committee-votes-peptides-what-it-does-and

6. FDA Law Blog, "FDA's Pep(tide) Rally! What Compounders and Industry Need to Know (Post 1 of 2)," April 2026. https://www.thefdalawblog.com/2026/04/fdas-peptide-rally-what-compounders-and-industry-need-to-know-post-1-of-2/

7. STAT, "In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides," July 23, 2026. https://www.statnews.com/2026/07/23/fda-panel-okays-peptides-compound-pharmacies-bpc-157-kpv/

8. NPR, "FDA advisers vote to ease peptide restrictions, despite agency concerns," July 23, 2026. https://www.npr.org/2026/07/23/nx-s1-5903202/fda-peptides-restrictions

9. Mondaq, "FDA Removes Certain Peptide Bulk Drug Substances From Category 2 Of Interim 503A Bulks List And Sets Dates For PCAC Review." https://www.mondaq.com/unitedstates/life-sciences-biotechnology-nanotechnology/1526254/fda-removes-certain-peptide-bulk-drug-substances-from-category-2-of-interim-503a-bulks-list-and-sets-dates-for-pcac-review

10. Federal Register, "Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List; Revisions to the Withdrawn or Removed List," document 2024-21241, 89 FR 76478, published September 18, 2024. https://www.federalregister.gov/documents/2024/09/18/2024-21241/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request

11. U.S. Food and Drug Administration, "October 29, 2024: Meeting of the Pharmacy Compounding Advisory Committee." https://www.fda.gov/advisory-committees/advisory-committee-calendar/october-29-2024-meeting-pharmacy-compounding-advisory-committee-10292024

12. Alliance for Natural Health USA, "FDA Strikes Another Blow Against Compounded Medicines: Peptides Rejected at Latest PCAC Meeting." https://anh-usa.org/fda-strikes-another-blow-against-compounded-medicines-peptides-rejected-at-latest-pcac-meeting/

*MyProtocolStack is a tracking and education tool, not medical advice, diagnosis, or treatment, and you should always consult a qualified healthcare professional before making any changes to your health protocol.*